Effect of CYP2C9 genetic polymorphism and breviscapine on losartan pharmacokinetics in healthy subjects

References

• Chu, Q., et al., 2005. Simultaneous determination of active ingredients in Erigeron breviscapus (Vant.) Hand-Mazz. by capillary electrophoresis with electrochemical detection. Journal of pharmaceutical and biomedical analysis, 37 (3), 535–541.
   PubMed Web of Science ®Google Scholar
• Faucette, S.R., et al., 2000. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug metabolism and disposition: the biological fate of chemicals, 28 (10), 1222–1230.
   PubMed Web of Science ®Google Scholar
• Gao, J., et al., 2017. Therapeutic effects of breviscapine in cardiovascular diseases: a review. Frontiers in pharmacology, 8, 289.
   PubMed Web of Science ®Google Scholar
• Gardin, A., et al., 2018. Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects. European journal of clinical pharmacology, 74 (12), 1593–1604.
   PubMed Web of Science ®Google Scholar
• Gonzalez, L., et al., 2002. Fast screening method for the determination of angiotensin II receptor antagonists in human plasma by high-performance liquid chromatography with fluorimetric detection. Journal of chromatography. A, 949 (1–2), 49–60.
   PubMed Web of Science ®Google Scholar
• Gunes, A., et al., 2007. Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients. Basic & clinical pharmacology & toxicology, 100 (6), 383–386.
   PubMed Web of Science ®Google Scholar
• Han, Y.L., et al., 2012. Evaluation of impact of Herba Erigerontis injection, a Chinese herbal prescription, on rat hepatic cytochrome P450 enzymes by cocktail probe drugs. Journal of ethnopharmacology, 139 (1), 104–109.
   PubMed Web of Science ®Google Scholar
• Han, Y., et al., 2009. Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers. European journal of clinical pharmacology, 65 (6), 585–591.
   PubMed Web of Science ®Google Scholar
• Jin, Y., et al., 2018. In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics. European journal of clinical pharmacology, 74 (4), 455–464.
   PubMed Web of Science ®Google Scholar
• Kirchheiner, J., and Brockmoller, J., 2005. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clinical pharmacology and therapeutics, 77 (1), 1–16.
   PubMed Web of Science ®Google Scholar
• Kobayashi, M., et al., 2008. The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan. Drug metabolism and pharmacokinetics, 23 (2), 115–119.
   PubMed Web of Science ®Google Scholar
• Lee, C.R., Goldstein, J.A., and Pieper, J.A., 2002. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics, 12 (3), 251–263.
   PubMedGoogle Scholar
• Lee, Y.J., et al., 2015. Effects of CYP2C9*1/*3 genotype on the pharmacokinetics of flurbiprofen in Korean subjects. Archives of pharmacal research, 38 (6), 1232–1237.
   PubMed Web of Science ®Google Scholar
• Liao, S.G., et al., 2010. Rapid screening and identification of caffeic acid and its esters in Erigeron breviscapus by ultra-performance liquid chromatography/tandem mass spectrometry. Rapid communications in mass spectrometry : RCM, 24 (17), 2533–2541.
   PubMed Web of Science ®Google Scholar
• Lin, Z., et al., 2014. In vivo effects of scutellarin on the activities of CYP1A2, CYP2C11, CYP2D1, and CYP3A1/2 by cocktail probe drugs in rats. Pharmazie, 69, 537–541.
   PubMed Web of Science ®Google Scholar
• Liu, Y., et al., 2013. UPLC-MS-MS method for simultaneous determination of caffeine, tolbutamide, metoprolol, and dapsone in rat plasma and its application to cytochrome P450 activity study in rats. Journal of chromatographic science, 51 (1), 26–32.
   PubMed Web of Science ®Google Scholar
• Lo, M.W., et al., 1995. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clinical pharmacology and therapeutics, 58 (6), 641–649.
   PubMed Web of Science ®Google Scholar
• Manikandan, P., and Nagini, S., 2018. Cytochrome P450 structure, function and clinical significance: a review. Current cancer drug targets, 19, 38–54.
   Google Scholar
• Mccrea, J.B., et al., 1999. Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clinical pharmacology and therapeutics, 65 (3), 348–352.
   PubMed Web of Science ®Google Scholar
• Pedreros-Rosales, C., et al., 2019. [Association between cytochrome p4502c9 polymorphisms and losartan dosing in hypertensive patients]. Revista medica de Chile, 147 (12), 1527–1534.
   PubMed Web of Science ®Google Scholar
• Pelkonen, O., et al., 2008. Inhibition and induction of human cytochrome P450 enzymes: current status. Archives of toxicology, 82 (10), 667–715.
   PubMed Web of Science ®Google Scholar
• Polinko, M., et al., 2003. Simultaneous determination of losartan and EXP3174 in human plasma and urine utilizing liquid chromatography/tandem mass spectrometry. Journal of pharmaceutical and biomedical analysis, 33 (1), 73–84.
   PubMed Web of Science ®Google Scholar
• Preskorn, S.H., et al., 2007. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline. Journal of psychiatric practice, 13 (1), 5–12.
   PubMedGoogle Scholar
• Quintieri, L., et al., 2010. Flavonoids diosmetin and hesperetin are potent inhibitors of cytochrome P450 2C9-mediated drug metabolism in vitro. Drug metabolism and pharmacokinetics, 25 (5), 466–476.
   PubMed Web of Science ®Google Scholar
• Sekino, K., et al., 2003. Effect of the single CYP2C9*3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. European journal of clinical pharmacology, 59 (8–9), 589–592.
   PubMed Web of Science ®Google Scholar
• Si, D., et al., 2004. Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics, 14 (7), 465–469.
   PubMedGoogle Scholar
• Sica, D.A., Gehr, T.W., and Ghosh, S., 2005. Clinical pharmacokinetics of losartan. Clinical pharmacokinetics, 44 (8), 797–814.
   PubMed Web of Science ®Google Scholar
• Sipeky, C., et al., 2009. Interethnic differences of CYP2C9 alleles in healthy Hungarian and Roma population samples: relationship to worldwide allelic frequencies. Blood cells, molecules, and diseases, 43 (3), 239–242.
   PubMed Web of Science ®Google Scholar
• Stearns, R.A., et al., 1995. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug metabolism and disposition: the biological fate of chemicals, 23 (2), 207–215.
   PubMed Web of Science ®Google Scholar
• Sullivan-Klose, T.H., et al., 1996. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 6 (4), 341–349.
   PubMedGoogle Scholar
• Tannenbaum, C., and Sheehan, N.L., 2014. Understanding and preventing drug-drug and drug-gene interactions. Expert review of clinical pharmacology, 7 (4), 533–544.
   PubMed Web of Science ®Google Scholar
• Triggle, D.J., 1995. Angiotensin II receptor antagonism: losartan - sites and mechanisms of action. Clinical therapeutics, 17 (6), 1005–1030.
   PubMed Web of Science ®Google Scholar
• Vormfelde, S.V., et al., 2009. Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. Clinical pharmacology and therapeutics, 86 (1), 54–61.
   PubMed Web of Science ®Google Scholar
• Wang, H., and Tompkins, L.M., 2008. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Current drug metabolism, 9 (7), 598–610.
   PubMed Web of Science ®Google Scholar
• Wennerholm, A., et al., 2006. Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo. European journal of clinical pharmacology, 62 (7), 539–546.
   PubMed Web of Science ®Google Scholar
• Williamson, K.M., et al., 1998. Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clinical pharmacology & therapeutics, 63 (3), 316–323.
   PubMed Web of Science ®Google Scholar
• Yan, L., et al., 2010. Breviscapine protects against cardiac hypertrophy through blocking PKC-alpha-dependent signaling. Journal of cellular biochemistry, 109 (6), 1158–1171.
   PubMed Web of Science ®Google Scholar
• Yin, T., et al., 2008. Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertension research : official journal of the Japanese society of hypertension, 31 (8), 1549–1557.
   PubMed Web of Science ®Google Scholar
• Yun, C.H., et al., 1995. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug metabolism and disposition: the biological fate of chemicals, 23 (2), 285–289.
   PubMed Web of Science ®Google Scholar
• Zhang, J.-L., et al., 2003. Study on metabolism of scutellarin in rats by HPLC-MS and HPLC-NMR. Journal of Asian natural products research, 5 (4), 249–256.
   PubMed Web of Science ®Google Scholar
• Zhou, S.F., Liu, J.P., and Chowbay, B., 2009. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug metabolism reviews, 41 (2), 89–295.
   PubMed Web of Science ®Google Scholar
• Zhou, X., et al., 2018. Effect of breviscapine on CYP3A metabolic activity in healthy volunteers. European journal of clinical pharmacology, 74 (1), 37–44.
   PubMed Web of Science ®Google Scholar